Journal article
Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma
Expert review of anticancer therapy, Vol.11(3), pp.443-455
03/01/2011
DOI: 10.1586/era.11.9
PMID: 21417857
Abstract
Monoclonal antibodies are commonly used in combination with chemotherapy when treating non-Hodgkin's lymphoma. Superior clinical benefits of chemotherapy-antibody combinations have been convincingly demonstrated in the setting of initial therapy in large randomized trials for many of the most common lymphoma subtypes. Clinicians have extrapolated from data in the initial treatment setting to justify chemotherapy-antibody combinations in the treatment of relapsed lymphoma. Many Phase II studies of chemotherapy-antibody combinations in relapsed lymphoma reviewed herein demonstrate clinical activity, and several randomized Phase III trials demonstrate superior clinical results when antibody is added to chemotherapy regimens in relapsed patients who have not previously been exposed to antibodies. Less clear is whether antibodies add to the clinical benefit of chemotherapy when patients have previously been exposed to antibodies, much less in the setting of patients who did not have a good result to a previous antibody-containing treatment plan.
Details
- Title: Subtitle
- Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma
- Creators
- Ahmad S HalwaniBrian K Link
- Resource Type
- Journal article
- Publication Details
- Expert review of anticancer therapy, Vol.11(3), pp.443-455
- Publisher
- Taylor & Francis
- DOI
- 10.1586/era.11.9
- PMID
- 21417857
- ISSN
- 1473-7140
- eISSN
- 1744-8328
- Language
- English
- Date published
- 03/01/2011
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984094571302771
Metrics
12 Record Views